Sangamo Biosciences on the Brink: Cash Crunch Could Lead to Bankruptcy by Q3 2024

Sangamo Biosciences faces a precarious financial future, as its cash reserves are projected to sustain operations only until the third quarter of 2024. Despite active efforts to raise additional capital, the company’s inability to secure further funding has compelled it to consider bankruptcy protection as a possible recourse. Should Sangamo file for bankruptcy, the company’s operational continuity, product development, and overall survival would be fraught with uncertainty, including potential liquidation.